| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cancer | |||||
| Carcinoma, Renal Cell | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Carcinoma | |||||
| 3 | More general conditions related to this trial | ||||
| Adenocarcinoma | |||||
| Kidney Diseases | |||||
| Kidney Neoplasms | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Urogenital Neoplasms | |||||
| Urologic Diseases | |||||
| Urologic Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| Nexavar (Sorafenib, BAY 43-9006) | |||||
| Placebo | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Sorafenib | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Protein Kinase Inhibitors | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Bayer | |||||
| ONYX Pharmaceuticals | |||||
|
